Benchmark’s vision is to be the leading provider of solutions in aquaculture genetics, health and specialist nutrition.
Our Investment Proposition
High growth markets
Focus on established, fast growing markets of genetics, health and specialist nutrition serving the increasingly important aquaculture sector.
Unique model
Benchmark has a differentiated model bringing together genetics, health and specialist nutrition, which combined can contribute significantly to improve the sustainability and profitability of aquaculture producers.
Barriers to competition
Market leadership, strong patent portfolio, long established breeding programmes and accredited manufacturing capability.
Scalable
Global distribution network and production capacity to support growth.
Potential to deliver high shareholder returns
High growth profile and target 25% EBITDA margin within 3 to five years.
Our Key Markets
5-7%
Projected growth (2018-2020)1
5%
Projected growth (2015-2019)2
5%
Projected growth per annum2
1 GOAL (2017) Global Shrimp Production Review and Forecast.
2 Rabobank, 2017.
Investor Factsheet
PDF, 590 KB
Three core divisions with strong market positions
Genetics
Breeding for the future with genomic precision.
- Market position
The leading player in the highly concentrated salmon industry - Global Customers
316 customers in c.30 countries; top 5: 29% (FY17 revenue) - Species
Salmon, shrimp, tilapia and breeding programmes for 15 species - Main sites
Norway, Iceland, Latam. Land based bio-secure facilities in Iceland and Norway - Products
High genetic quality ova for salmon, shrimp and tilapia, and breeding programmes - Employees 128
- 2017 Revenue £30.5m
Advanced Nutrition
High performance and cost-effective nutritional solutions.
- Market position
25% estimated share in global hatchery segment (fsh and shrimp). (40% of fastest growing Asian market excl. China) - Global Customers
614 customers in 70 countries; top 5: 37% (FY17 revenue) - Species
Shrimp and marine finfish - Main sites
Thailand, US, Belgium, Italy - Products
Specialist feeds for early stage shrimp and fnfsh; probiotics. Access to world’s greatest source of quality artermia - Employees 461
- 2017 Revenue £83.7m
Animal Health
Cutting edge health products targeted at the major disease challenges.
- Market position
A leader in salmon lice treatments and top 4 player in aquaculture health. Product pipeline positioned to become a leading innovator - Global Customers
426 customers in c.30 countries; top 5: 53% (FY17 revenue) - Species
Salmon, shrimp, tilapia, sea bass/sea bream - Main sites UK
- Products
Vaccines, biocides, medicines - Employees 177
- 2017 Revenue £15.1m
Focused on the execution and launch of our rich pipeline of products
2017 Financial Headline
| £m | 2017 | 2016 |
|---|---|---|
| Total revenue | 140.2 | 109.4 |
| Research and development costs | (13.1) | (11.7) |
| Adjusted EBITDA | 10.0 | 9.2 |
| Exceptional including acquisition related items | 5.6 | (13.1) |
| Loss before tax | (8.1) | (22.4) |
| Basic loss per share (pence) | (1.4) | (4.4) |
Revenue split by divisions (FY17)
- Genetics
- Advanced Nutrition
- Health
- Knowledge Services